Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...
Cetuximab combined with chemotherapy significantly improves PFS and OS in mCRC patients, as confirmed by a meta-analysis of 25 studies. The study highlights cetuximab's efficacy, despite ...
Yonhap News English on MSN1mon
Celltrion gets U.S. FDA approval for new biosimilar for autoimmune disease treatmentSEOUL, Jan. 31 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback